Antithrombin and hypercoagulability in sepsis: Insights from thrombelastography?

Critical Care

Volumn 11, Issue 1, 2007, Pages

  Hoffmann, Johannes N ^a   Schick, Kerstin ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN; HEPARIN;

BLOOD CLOTTING TEST; CLINICAL EVALUATION; CLINICAL TRIAL; CORRELATION ANALYSIS; DISEASE SEVERITY; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG EFFICACY; DRUG INDICATION; DRUG MEGADOSE; DRUG TREATMENT FAILURE; HUMAN; HYPERCOAGULABILITY; MORTALITY; NOTE; PRIORITY JOURNAL; SCORING SYSTEM; SENSITIVITY ANALYSIS; SEPSIS; SURVIVAL RATE; THROMBOELASTOGRAPHY; TREATMENT DURATION; TREND STUDY; VALIDATION PROCESS; THROMBOPHILIA;

ANTITHROMBINS; HUMANS; SEPSIS; THROMBELASTOGRAPHY; THROMBOPHILIA;

EID: 34248173380     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc5156     Document Type: Note

References (11)

1. Gonano C Sitzwohl C Meitner E Weinstabl C Kettner SC Four-day antithrombin therapy does not seem to attenuate hypercoagulability in patients suffering from sepsis Crit Care 2006, 10:R160. 1794466 17107615 10.1186/cc5098
2. Bone RC Modulators of coagulation. A critical appraisal of their role in sepsis Arch Intern Med 1992, 152:1381-1389. 10.1001/archinte.152.7.1381 1627018
3. Cohen JR Sarfati I Birnbaum E Benacquista T Wise L The inactivation of antithrombin III by serum elastase in patients with surgical infections Am Surg 1990, 56:665-667. 2240857
4. Blatt PM White GC 2nd Goldsmith JC Roberts HR Antithrombin-III transfusion in disseminated intravascular coagulation Lancet 1978, 1:1212. 10.1016/S0140-6736(78)91006-1 77980
5. Warren BL Eid A Singer P Pillay SS Carl P Novak I Chalupa P Atherstone A Penzes I Kübler A High-dose antithrombin III in severe sepsis: A randomized controlled trial JAMA 2001, 286:1869-1878. 10.1001/ jama.286.15.1869 11597289
6. Hoffmann JN Wiedermann CJ Juers M Ostermann H Kienast J Briegel J Strauss R Warren BL Opal SM Benefit/risk profile of high-dosed antithrombin in patients with severe sepsis treated with and without concomitant heparin Thromb Hemost 2006, 95:850-856. 16676077
7. Kienast J Juers M Wiedermann CJ Hoffmann JN Ostermann H Strauss R Keinecke HO Warren BL Opal SM Kybersept Investigators Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation J Thromb Haemost 2006 4 90 10.1111/j.1538-7836.2005.01697.x 16409457
8. Angstwurm MW Dempfle CE Spannagl M New disseminated intravascular coagulation score: A useful tool to predict mortality in comparison with Acute Physiology and Chronic Health Evaluation II and Logistic Organ Dysfunction scores Crit Care Med 2006, 34:314-20. quiz 328 10.1097/ 01.CCM.0000196832.27501.B2 16424708
9. Fourrier F Chopin C Huart JJ Runge I Caron C Goudemand J Double-blind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation Chest 1993, 104:882-888. 8365305
10. Hoffmann JN Muhlbayer D Jochum M Inthorn D Effect of long-term and high-dose antithrombin supplementation on coagulation and fibrinolysis in patients with severe sepsis Crit Care Med 2004, 32:1851-1859. 10.1097/ 01.CCM.0000139691.54108.1F 15343012
11. Hoffmann JN Vollmar B Laschke MW Fertmann JM Jauch KW Menger MD Microcirculatory alterations in ischemia reperfusion injury and sepsis: effects of activated protein C and thrombin inhibition Crit Care 2005, 9(Suppl 4):S33-37. 10.1186/cc3758 16168073